Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a case report.
Abacavir is a nucleoside analogue reverse transcriptase inhibitor used in combination with other antiretroviral drugs for the treatment of HIV 1-infection. Approximately 3% of patients who receive abacavir develop an idiosyncratic hypersensitivity reaction. The most common symptoms are fever, skin rash and gastrointestinal disorders. Respiratory symptoms occurred in approximately 20% of patients who have hypersensitivity reaction. We describe the first case, to our knowledge, of hypesensitivity reaction characterized by enanthema and fever without skin rash promptly resolved after discontinuation of abacavir
Divisione Clinicizzata di Malattie Infettive, Istituto di Immunologia e Malattie Infettive, Ospedale Civile Maggiore di Borgo Trento, Verona, Italy.
Massimilliano
M
Lanzafame
Marco
M
Trevenzoli
Emanuela
E
Lattuada
Federica
F
Faggian
Sandro
S
Vento
Ercole
E
Concia
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015224:Dideoxynucleosides / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D008297:Male; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D000099227:Abacavir